
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent
Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.
Date:2020-12-28